{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["140(8)"],"submitter":["Heiblig M"],"journal":["Blood"],"pagination":["927-931"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9412002"],"repository":["biostudies-literature"],"pubmed_title":["Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study."],"pmcid":["PMC9412002"],"pubmed_authors":["Bigot A","Grayson PC","Galland J","Bienvenu B","Fenaux P","Mekinian A","Vial G","Jamilloux Y","Galicier L","Sujobert P","Coelho H","Boutin AB","Warrington KJ","Gerfaud-Valentin M","Fossard G","Ferrada MA","Heiblig M","Beck DB","Le Guenno G","Barba T","Kermani TA","Patel BA","Hirsch P","Koster MJ","Barraco F"],"additional_accession":[]},"is_claimable":false,"name":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.","description":null,"dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-04T20:07:38.731Z","creation":"2025-04-04T20:07:38.731Z"},"accession":"S-EPMC9412002","cross_references":{"pubmed":["35609174"],"doi":["10.1182/blood.2022016642"]}}